Appleton Partners Inc. MA Has $7.22 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Appleton Partners Inc. MA decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,917 shares of the company’s stock after selling 5,330 shares during the quarter. Appleton Partners Inc. MA’s holdings in Johnson & Johnson were worth $7,219,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of JNJ. IFS Advisors LLC boosted its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $31,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $32,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on JNJ. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Raymond James cut their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Price Performance

JNJ stock opened at $154.22 on Tuesday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s fifty day simple moving average is $147.42 and its 200 day simple moving average is $156.08. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The firm has a market cap of $371.31 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the company earned $2.29 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.22%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.